5 Stocks Improving Performance Of The Diversified Services Industry

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 79 points (0.5%) at 15,467 as of Wednesday, May 22, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,746 issues advancing vs. 1,183 declining with 133 unchanged.

The Diversified Services industry currently sits up 0.2% versus the S&P 500, which is up 0.5%. Top gainers within the industry include Booz Allen Hamilton ( BAH), up 7.2%, KBR ( KBR), up 2.4%, Visa ( V), up 0.8% and Hertz Global Holdings ( HTZ), up 0.9%. A company within the industry that fell today was Priceline.com ( PCLN), up 1.81.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Qiagen ( QGEN) is one of the companies pushing the Diversified Services industry higher today. As of noon trading, Qiagen is up $0.44 (2.37) to $19.02 on average volume Thus far, 533,195 shares of Qiagen exchanged hands as compared to its average daily volume of 810,500 shares. The stock has ranged in price between $18.84-$19.03 after having opened the day at $18.86 as compared to the previous trading day's close of $18.58.

QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. Qiagen has a market cap of $4.3 billion and is part of the services sector. The company has a P/E ratio of 34.3, above the S&P 500 P/E ratio of 17.7. Shares are up 2.4% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Qiagen a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Qiagen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Qiagen Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

What IBM's Genomic Partnership With Quest Says About Thermo Fisher, Diagnostics Peers

3 Diversified Services Stocks Nudging The Industry Higher

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Watch Out: Barbarians At The Gate For Qiagen (QGEN)